GLP-1 Weight Loss Drugs Effective Even at Low Starter Doses
Patients on starter doses still lost weight, with 5.5% average loss on tirzepatide and 2.2% on semaglutide after one year, researchers said.
4 Articles
4 Articles
GLP-1 weight loss drugs effective even at low starter doses
The GLP-1 drugs semaglutide, sold as Ozempic and Wegovy by Novo Nordisk, and Eli Lilly's tirzepatide, sold under the brand names Mounjaro and Zepbound, are prescribed initially at a low dose followed by gradual titration to higher doses, to help the body adjust and minimize side effects
GLP-1 weight loss drugs effective even at low starter doses - Regional Media News
By Nancy Lapid Aug 31 (Reuters) - People taking popular GLP-1 obesity drugs who remain on low starter doses will lose some weight but may still experience side effects, although significantly less nausea than those who graduate to higher manufacturer-recommended doses, a new study suggests. [...]
GLP-1-based medications, such as semaglutide and tirrizepatide, are generally prescribed at a low initial dose, followed by a gradual adjustment to higher doses.
Side effects are also fewer, according to a new real-world study. What was observed at the level of kidney function. People taking GLP-1 drugs to treat obesity can lose weight even when they stay at lower starting doses, without moving on to higher maintenance doses. The weight loss is significantly less, but some of the side effects also seem to be limited, according to a new study. Treatments with semaglutide and tirzepatide usually start at l…
Coverage Details
Bias Distribution
- 50% of the sources lean Left, 50% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
